Javlor Falls Short Again At NICE; Even Sole Treatment In Class Faces Cost Hurdle
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE questions the cost and clinical effectiveness Pierre Fabre’s Javlor for metastatic transitional cell carcinoma in a disappointing final appraisal for the drug.